Episode
Real Family Perspectives on Treating Bleeding Disorders with Inhibitors with Andrea Buxton & Kristy Schiffer Part I
- Podcast
- Beyond the Bleeds
- Published
- Dec 8, 2025
- Duration seconds
- 1992
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/beyond-the-bleeds-7074228/episodes/real-family-perspectives-on-treating-bleeding-disorders-with-inhibitors-with-andrea-buxton-kristy-schiffer-part-i/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/beyond-the-bleeds-7074228/real-family-perspectives-on-treating-bleeding-disorders-with-inhibitors-with-andrea-buxton-kristy-schiffer-part-i.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Today on Beyond the Bleeds, we sit down with Andrea Buxton and Kristy Schiffer to explore the world of inhibitors in bleeding disorders. We unravel what inhibitors are, why they develop, who’s most at risk, and the profound impact these immune system complications have on treatment, families, and daily life. Our guests share not just the science but the real-world journey, filled with challenges, advocacy, and breakthroughs in care for children like Kristy’s son navigating severe hemophilia and inhibitors. Andrea Buxton serves as the nurse practitioner and clinical director at the Hemophilia Outreach Center (HOC). With her depth of experience treating inherited bleeding disorders, Andrea is known for combining her clinical expertise with an ability to translate complex medical topics into practical advice for families. Her advocacy and leadership have improved protocols and advanced support for patients confronting inhibitors and the evolving treatments in hemophilia care. “Essentially, when a patient is born with severe hemophilia…their body is not producing a normal level of the clotting protein, Factor VIII or Factor IX.” ~Andrea Buxton Today on Beyond the Bleeds: Inhibitors develop when the body’s immune system responds to infused clotting factor proteins as foreign substances and creates antibodies against them. Severe hemophilia patients are at the highest risk for developing inhibitors, especially those with no naturally occurring Factor VIII or IX. Family history matters, but about 30% of severe hemophilia mutations are spontaneous and undetected until a major bleed occurs. Signs of an inhibitor may include a patient not responding to standard factor treatment and experiencing breakthrough bleeds; regular testing is crucial. Treatment changes drasti…